Klingenstein Fields & Co’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$27M Sell
224,870
-5,048
-2% -$583K 1.07% 32
2025
Q4
$24.2M Sell
229,918
-2,403
-1% -$226K 0.91% 32
2025
Q3
$19.5M Buy
232,321
+41
+0% +$3.38K 0.74% 40
2025
Q2
$18.4M Sell
232,280
-51,041
-18% -$4.06M 0.73% 44
2025
Q1
$25.4M Buy
283,321
+2,465
+0.9% +$230K 1.08% 33
2024
Q4
$27.9M Buy
280,856
+1,658
+0.6% +$171K 1.13% 31
2024
Q3
$31.7M Sell
279,198
-5,680
-2% -$675K 1.26% 30
2024
Q2
$35.3M Sell
284,878
-19,597
-6% -$2.52M 1.46% 23
2024
Q1
$40.2M Sell
304,475
-8,444
-3% -$1.04M 1.67% 16
2023
Q4
$34.1M Sell
312,919
-2,457
-0.8% -$255K 1.52% 20
2023
Q3
$32.5M Sell
315,376
-618
-0.2% -$66.6K 1.59% 19
2023
Q2
$36.5M Sell
315,994
-3,684
-1% -$418K 1.69% 17
2023
Q1
$34M Sell
319,678
-3,874
-1% -$418K 1.7% 17
2022
Q4
$35.9M Sell
323,552
-7,702
-2% -$787K 1.86% 15
2022
Q3
$28.5M Buy
331,254
+222
+0.1% +$19.8K 1.57% 19
2022
Q2
$30.2M Buy
331,032
+34
+0% +$3.01K 1.57% 20
2022
Q1
$27.2M Buy
330,998
+2,342
+0.7% +$185K 1.16% 35
2021
Q4
$25.2M Sell
328,656
-5,666
-2% -$451K 1.01% 39
2021
Q3
$25.1M Buy
334,322
+580
+0.2% +$44.1K 1.07% 36
2021
Q2
$26M Sell
333,742
-12,650
-4% -$941K 1.07% 36
2021
Q1
$25.5M Buy
346,392
+2,066
+0.6% +$152K 1.15% 31
2020
Q4
$26.9M Buy
344,326
+1,269
+0.4% +$97.1K 1.22% 28
2020
Q3
$27.2M Sell
343,057
-2,657
-0.8% -$208K 1.36% 23
2020
Q2
$25.5M Sell
345,714
-927
-0.3% -$69.8K 1.39% 23
2020
Q1
$25.4M Sell
346,641
-582
-0.2% -$45.7K 1.66% 16
2019
Q4
$30.1M Sell
347,223
-7,615
-2% -$625K 1.52% 20
2019
Q3
$28.5M Sell
354,838
-5,698
-2% -$457K 1.5% 22
2019
Q2
$28.8M Sell
360,536
-9,327
-3% -$714K 1.5% 19
2019
Q1
$29.4M Sell
369,863
-116,852
-24% -$8.74M 1.58% 17
2018
Q4
$35.5M Sell
486,715
-12,390
-2% -$875K 1.51% 16
2018
Q3
$33.8M Buy
499,105
+16,522
+3% +$1.05M 1.21% 24
2018
Q2
$28M Buy
482,583
+16,121
+3% +$909K 1.07% 33
2018
Q1
$24.2M Buy
466,462
+677
+0.1% +$36.6K 0.93% 41
2017
Q4
$25M Buy
465,785
+2,652
+0.6% +$147K 0.92% 42
2017
Q3
$28.3M Sell
463,133
-6,979
-1% -$423K 1.09% 32
2017
Q2
$28.7M Buy
470,112
+2,232
+0.5% +$136K 1.13% 33
2017
Q1
$28.4M Buy
467,880
+24,060
+5% +$1.46M 1.15% 27
2016
Q4
$24.9M Buy
443,820
+4,798
+1% +$281K 1.09% 31
2016
Q3
$26.1M Sell
439,022
-1,916
-0.4% -$112K 1.2% 24
2016
Q2
$24.2M Buy
440,938
+296,671
+206% +$15.8M 1.13% 27
2016
Q1
$7.28M Buy
144,267
+47,069
+48% +$2.31M 0.36% 62
2015
Q4
$4.9M Buy
97,198
+36,471
+60% +$1.84M 0.24% 72
2015
Q3
$2.86M Buy
60,727
+14,776
+32% +$785K 0.14% 87
2015
Q2
$2.5M Sell
45,951
-3,626
-7% -$203K 0.11% 92
2015
Q1
$2.72M Sell
49,577
-524
-1% -$29.7K 0.12% 93
2014
Q4
$2.71M Sell
50,101
-917
-2% -$51.1K 0.12% 89
2014
Q3
$2.89M Hold
51,018
0.13% 88
2014
Q2
$2.82M Sell
51,018
-8,493
-14% -$463K 0.12% 93
2014
Q1
$3.22M Sell
59,511
-111,675
-65% -$5.78M 0.14% 85
2013
Q4
$8.18M Sell
171,186
-4,121
-2% -$188K 0.29% 76
2013
Q3
$7.96M Sell
175,307
-55,235
-24% -$2.52M 0.31% 72
2013
Q2
$10.2M Buy
+230,542
New +$10.3M 0.37% 76

Other funds holding MRK

Klingenstein Fields & Co's MRK Position: Q1 2026 in Review

Klingenstein Fields & Co reduced its Merck (MRK) stake by 2.2% in Q1 2026, selling an estimated $583K and leaving 224,870 shares worth $27M. The position accounts for 1.07% of the portfolio, ranked #32.

Klingenstein Fields & Co first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.2M in Q1 2024. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Klingenstein Fields & Co held 224,870 shares of Merck worth $27M as of Q1 2026.
  • Klingenstein Fields & Co sold 5,048 Merck shares in Q1 2026, an estimated $583K.
  • Merck made up 1.07% of Klingenstein Fields & Co's portfolio in Q1 2026, its #32 holding.
  • Klingenstein Fields & Co first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Klingenstein Fields & Co's Merck position peaked at $40.2M in Q1 2024.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Klingenstein Fields & Co's 13F filing for Q1 2026, filed 13 May 2026.